Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 4/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.38 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22291214 | 0.79 | SMPD3 (0.58) | SMPD3MGAMGAASIMGAM2 | |
| SCHEMBL22301855 | 0.74 | CDK4 (0.56) | CDK4CCND1PARP1DHODHLMNA | |
| SCHEMBL22291111 | 0.72 | SMPD3 (0.64) | CDK4CCND1PARP1PARP2MAPT | |
| SCHEMBL29580411 | 0.71 | ALDH1A1 (0.58) | CDK4CCND1LMNAMAPTHTT | |
| SCHEMBL14771418 | 0.68 | MGAM (0.38) | MGAMGAASIMGAM2HPSE | |
| SCHEMBL14421949 | 0.67 | ACHE (0.58) | LMNAHTT | |
| SCHEMBL21474636 | 0.65 | MGAM (0.61) | MGAMGAASIMGAM2 | |
| SCHEMBL2494177 | 0.64 | CASR (0.49) | PARP1PARP2MGAMGAASI | |
| SCHEMBL2456957 | 0.64 | CYP1A2 (0.46) | — | |
| SCHEMBL10508622 | 0.63 | MGAM (0.60) | PARP1DHODHLMNAMGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119374-A1 | SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (nSMase2) INHIBITORS | THE JOHNS HOPKINS UNIVERSITY | 2022-04-21 | — | — | US | disclosed |
| WO-2020160148-A1 | SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (NSMASE2) INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119374-A1 | SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (nSMase2) INHIBITORS | SMPD2, SPTLC2, SGMS2 | CDK4 3727/4885CCND1 3250/4885PARP1 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.